Association of sleep disturbance and freezing of gait in Parkinson disease: prevention/delay implications

Author(s):  
Xiaohui Tang ◽  
Lijia Yu ◽  
Jingyun Yang ◽  
Wenjing Guo ◽  
Ying Liu ◽  
...  
Neurology ◽  
2020 ◽  
Vol 95 (3) ◽  
pp. e280-e290 ◽  
Author(s):  
Seok Jong Chung ◽  
Hye Sun Lee ◽  
Han Soo Yoo ◽  
Yang Hyun Lee ◽  
Phil Hyu Lee ◽  
...  

ObjectiveTo investigate whether the patterns of striatal dopamine depletion on dopamine transporter (DAT) scans could provide information on the long-term prognosis in Parkinson disease (PD).MethodsWe enrolled 205 drug-naive patients with early-stage PD, who underwent 18F-FP-CIT PET scans at initial assessment and received PD medications for 3 or more years. After quantifying the DAT availability in each striatal subregion, factor analysis was conducted to simplify the identification of striatal dopamine depletion patterns and to yield 4 striatal subregion factors. We assessed the effect of these factors on the development of levodopa-induced dyskinesia (LID), wearing-off, freezing of gait (FOG), and dementia during the follow-up period (6.84 ± 1.80 years).ResultsThe 4 factors indicated which striatal subregions were relatively preserved: factor 1 (caudate), factor 2 (more-affected sensorimotor striatum), factor 3 (less-affected sensorimotor striatum), and factor 4 (anterior putamen). Cox regression analyses using the composite scores of these striatal subregion factors as covariates demonstrated that selective dopamine depletion in the sensorimotor striatum was associated with a higher risk for developing LID. Selective dopamine loss in the putamen, particularly in the anterior putamen, was associated with early development of wearing-off. Selective involvement of the anterior putamen was associated with a higher risk for dementia conversion. However, the patterns of striatal dopamine depletion did not affect the risk of FOG.ConclusionsThese findings suggested that the patterns of striatal dopaminergic denervation, which were estimated by the equation derived from the factor analysis, have a prognostic implication in patients with early-stage PD.


2021 ◽  
Vol 4 ◽  
pp. 100219
Author(s):  
Yuthim Oktiany Ranteallo ◽  
Yudy Goysal ◽  
Muhammad Iqbal Basri ◽  
Andi Kurnia Bintang ◽  
Muhammad Akbar

2018 ◽  
Vol 7 (2.31) ◽  
pp. 114
Author(s):  
Vivek Chowdhury ◽  
Arka Goswami ◽  
Rakshit Nigam ◽  
P A Sridhar

This paper primarily discusses the Freezing of Gait which is a type of gait abnormality and generally occurs in Parkinson Disease patients which cause an interruption to their life. During a FOG episode, the subject is rendered unable to continue moving or even manoeuver. These episodes give rise to the danger of the patient landing on the ground and often renders a person immobile. The aim of this device is to develop a technique to identify the effect of ‘Freezing of Gait’ in people suffering from Parkinsons Disease and to provide feedback on detection and improving self-efficiency in about their daily life.


Neurology ◽  
2009 ◽  
Vol 72 (8) ◽  
pp. 770-771 ◽  
Author(s):  
H. Brozova ◽  
I. Barnaure ◽  
R. L. Alterman ◽  
M. Tagliati ◽  
C. Moreau ◽  
...  

2014 ◽  
Vol 345 (1-2) ◽  
pp. 56-60 ◽  
Author(s):  
Ruwei Ou ◽  
Xiaoyan Guo ◽  
Wei Song ◽  
Bei Cao ◽  
Jing Yang ◽  
...  

Neurology ◽  
2018 ◽  
Vol 91 (2) ◽  
pp. 97-97
Author(s):  
Jorik Nonnekes ◽  
Bastiaan R. Bloem

2020 ◽  
Vol 34 (11) ◽  
pp. 967-978
Author(s):  
Bruno Braz Garcia ◽  
Edson Ricardo Junior ◽  
Mariana Ferreira Pereira de Araújo ◽  
Hougelle Simplício

Background Current available therapies for Parkinson disease (PD) have strong limitations, and patients usually present with refractory symptoms despite all efforts. Deep brain stimulation (DBS), which has been used in PD patients for decades (since 1987), has best indications for symptoms like tremor, motor fluctuations, or dyskinesia. However, postural instability and gait disturbances (PIGD) have restricted benefits with DBS. In 2009, spinal cord stimulation (SCS), a well-established therapy for chronic pain, has emerged as a potential alternative therapy that may help control unresponsive symptoms such as bradykinesia, PIGD, and freezing of gait. Methods The main studies regarding SCS in PD are reviewed here from the first studies in animal models to the latest clinical trials. Conclusions Despite promising findings, the heterogeneity of methodologies used and small samples in human studies pose a challenging problem to be addressed in order to have robust clinical evidence to support SCS as a viable PD treatment


Sign in / Sign up

Export Citation Format

Share Document